Kathleen Meyer

Kathleen Meyer

Auto-generated profile, based on publicly available information

Kathleen Meyer

Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST)

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in JACC
Verified
Journal Article
Closed access
KMKathleen Meyer
Kathleen Meyer
BHBettina Hodwin
Bettina Hodwin
DRDeepak Ramanujam
Deepak Ramanujam
SEStefan Engelhardt
Stefan Engelhardt
ASAntonio Sarikas
Antonio Sarikas

1 November 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
XXXinsong Xu
Xinsong Xu
MKMalik Keshwani
Malik Keshwani
KMKathleen Meyer
Kathleen Meyer
ASAntonio Sarikas
Antonio Sarikas
STSusan Taylor
Susan Taylor
ZPZhen-Qiang Pan
Zhen-Qiang Pan
Hyperactivation of mechanistic target of rapamycin complex 1 (mTORC1) and its effector kinase S6 kinase 1 (S6K1) is known to trigger multisite seryl phosphorylation of insulin receptor substrate 1 (IRS1), leading to its ubiquitination and degradation. This negative feedback inhibition functions to restrain PI3K activity and plays critical roles in the pathogenesis of cancer and type II diabetes. Recent work has implicated a role for cullin-RING E3 ubiquitin ligase 7 (CRL7) in targeting IRS1 for mTORC1/S6K1-dependent degradation. In the present study we have employed both cell-based degradation and reconstituted ubiquitination approaches to define molecular features associated with IRS1 critical for CRL7-mediated ubiquitination and degradation. We have mapped IRS1 degradation signal sequence to its N-terminal 574 amino acid residues, of which the integrity of Ser-307/Ser-312 and Ser-527, each constituting a S6K1 phosphorylation consensus site, was indispensible for supporting CRL7-forced degradation. In vitro, S6K1 was able to support the ubiquitination of bacterially expressed IRS1 N-terminal fragment by CRL7 but at low levels. In contrast, CRL7 supported efficient ubiquitination of IRS1 N-terminal fragment in hyperphosphorylated form, which was isolated from infected insect cells, suggesting requirement of additional phosphorylation by kinases yet to be identified. Finally, removal of IRS1 amino acids 1–260 led to substantial reduction of ubiquitination efficiency, suggesting a role for this region in mediating productive interactions with CRL7. The requirement of multisite phosphorylation and the N terminus of IRS1 for its turnover may ensure that complete IRS1 degradation occurs only when mTORC1 and S6K1 reach exceedingly high levels.

18 October 2011 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
EKElisabeth Kremmer
Elisabeth Kremmer
KMKathleen Meyer
Kathleen Meyer
FGFriedrich A. Grässer
Friedrich A. Grässer
AFAndrew Flatley
Andrew Flatley
MKMiwako Kösters
Miwako Kösters
Peter KramerPeter Kramer
Peter Kramer

18 February 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
THThomas Hartmann
Thomas Hartmann
XXXinsong Xu
Xinsong Xu
MKMira Kronast
Mira Kronast
SMSusanne Muehlich
Susanne Muehlich
KMKathleen Meyer
Kathleen Meyer
ASAntonio Sarikas
Antonio Sarikas
Significance: Simian virus 40 (SV40) large tumor antigen (LT) is a viral oncoprotein with the ability to induce tumors by inhibition of cellular tumor suppressors such as p53 and members of the retinoblastoma protein family. Here we present evidence for a role of SV40 LT in suppressing the activity of Cullin-RING E3 ubiquitin ligase 7 in mediating the ubiquitin-dependent degradation of insulin receptor substrate 1 (IRS1). This SV40 LT-mediated protection of IRS1 leads to enhanced activation of promitogenic downstream signaling pathways AKT and Erk mitogen-activated pathway kinase, which may contribute to viral-induced oncogenic transformation.

4 November 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SCSelim Chaib
Selim Chaib
JLJosé Alberto López-Domínguez
José Alberto López-Domínguez
MLMarta Lalinde
Marta Lalinde
NPNeus Prats
Neus Prats
IMInes Marin
Ines Marin
MSManuel Serrano
Manuel Serrano
Anti-cancer therapies often result in a subset of surviving cancer cells that undergo therapy-induced senescence (TIS). Senescent cancer cells strongly modify the intratumoural microenvironment favoring immunosuppression and, thereby, tumour growth. An emerging strategy to optimise current therapies is to combine them with treatments that eliminate senescent cells. To this end, we undertook an unbiased proteomics approach to identify surface markers contributing to senescent cells immune evasion. Through this approach, we discovered that the immune checkpoint inhibitor PD-L2, but not PD-L1, is upregulated across multiple senescent human and murine cells. Importantly, blockade of PD-L2 strongly synergises with genotoxic chemotherapy, causing remission of solid tumours in mice. We show that PD-L2 inhibition prevents the persistence of chemotherapy-induced senescent cells, which exert cell-extrinsic immunomodulatory actions. In particular, upon chemotherapy, tumours deficient in PD-L2 fail to produce cytokines of the CXCL family, do not recruit myeloid-derived suppressor cells (MDSCs) and are eliminated in a CD8 T cell-dependent manner. We conclude that blockade of PD-L2 improves chemotherapy efficacy by reducing the intratumoural burden of senescent cells and their associated recruitment of immunosuppressive cells. These findings provide a novel strategy to exploit vulnerabilities arising in tumour cells as a result of therapy-induced damage and cellular senescence.

1 May 2020
Verified
Conference Paper
Open access
Fernanda HernandezFernanda Hernandez
Fernanda Hernandez
FPFederico Pietrocola
Federico Pietrocola
NPN. Prats
N. Prats
KMK. Meyer
K. Meyer
JLJ.A. Lopez
J.A. Lopez
MSM. Serrano
M. Serrano